The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery

NCT06743802 | Recruiting Phase 4 DMC

• 1 other identifier: Coenzyme Q10 and pain
• Study Type: interventional
• Target: 264
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess the effectiveness of Coenzyme Q10 in preventing both acute and chronic pain following thoracoscopic surgery, with a focus on its potential benefits in reducing the incidence and severity of pain.

Conditions

Postoperative Pain

Outcome Measures

Primary Outcomes (1)

• The incidence of chronic postsurgical pain

  from the end of surgery to 3 months after surgery

Secondary Outcomes (10)

• The incidence of acute postoperative pain with a score ≥4

  from the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.

• The severity of acute postoperative pain

  from the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.

• The severity of chronic postsurgical pain

  from the end of surgery to 3 months after surgery

• The incidence of neuropathic pain

  from the end of surgery to 3 months after surgery

• The frequency of postoperative rescue analgesic use

  from the end of surgery to 6 hours,12 hours, 24 hours , 48 hours and 72 hours after surgery.

Study Arms (2)

Coenzyme Q10

EXPERIMENTAL

Drug: Coenzyme Q10

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

Coenzyme Q10 DRUG

Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).

Coenzyme Q10

Placebo OTHER

The placebo was administered from hospital admission until one month after discharge.

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18-75 years;
• American Society of Anesthesiology (ASA) physical status classification I-III;
• Scheduled for elective lung resection surgery under thoracoscopy;
• Voluntarily opting for patient-controlled intravenous analgesia;
• Willing to participate in this trial after consultation with the patient or their family and signing the informed consent form.

You may not qualify if:

• History of previous thoracotomy or thoracoscopic surgery;
• Patients converted to open thoracotomy intraoperatively;
• Severe hepatic or renal dysfunction;
• History of substance abuse;
• Pregnancy or breastfeeding;
• History of chronic pain;
• Use of coenzyme Q10 for more than one month;
• Allergy to coenzyme Q10;
• Patients unable to communicate or cooperate.

Sponsors & Collaborators

• The Second Affiliated Hospital of Chongqing Medical University: lead

Study Sites (1)

Guangyou Duan

Chongqing, Chongqing Municipality, 400010, China

RECRUITING

Related Publications (1)

• Liu J, Li L, Luo L, Wu N, Xu F, Tao C, Chen J, Huang H, Duan G. Effect of coenzyme Q10 on pain prevention after thoracoscopic surgery: study protocol. Pain Manag. 2025 Dec;15(12):889-896. doi: 10.1080/17581869.2025.2567832. Epub 2025 Sep 30.

  PMID: 41025845 DERIVED

MeSH Terms

Conditions

Pain, Postoperative

Interventions

coenzyme Q10

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms

Central Study Contacts

Guangyou Duan, ph.D

CONTACT

(+86)18323376014; duangy@hospital.cqmu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2024
• First Posted: December 20, 2024
• Study Start: January 9, 2025
• Primary Completion: March 20, 2026
• Study Completion: March 20, 2026
• Last Updated: February 26, 2025

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will share

Locations

CN (1)